MARKET

GNPX

GNPX

Genprex Inc
NASDAQ
4.200
-0.210
-4.76%
Closed 18:39 02/27 EST
OPEN
4.460
PREV CLOSE
4.410
HIGH
4.481
LOW
4.200
VOLUME
12.27K
TURNOVER
0
52 WEEK HIGH
54.00
52 WEEK LOW
4.010
MARKET CAP
6.24M
P/E (TTM)
-0.1709
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GNPX last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at GNPX last week (0212-0216)?
Weekly Report · 02/19 12:15
Weekly Report: what happened at GNPX last week (0205-0209)?
Weekly Report · 02/12 12:01
Genprex To Expand Non-clinical Program To Study TUSC2, NPRL2
NASDAQ · 02/07 14:21
Genprex Expands Nonclinical Programs Through Sponsored Research Agreements And Material Transfer Agreements To Study TUSC2 And NPRL2 Tumor Suppressor Genes
Benzinga · 02/07 13:20
Genprex Launches Phase 2a Reqorsa Trial Expansion
Genprex Inc (GNPX) has initiated the Phase 2a expansion of its Acclaim-1 clinical trial for Reqorsa Therapy. The first patient will be dosed in January 2024. The trial targets late-stage Non-Small Cell Lung Cancer patients.
TipRanks · 02/06 09:23
Genprex to Present at Upcoming BIO CEO & Investor Conference
Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes. Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming BIO CEO & Investor Conference. Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies.
Barchart · 02/06 06:30
CTLT, BTAI and CAMP are among pre market gainers
Seeking Alpha · 02/05 13:31
More
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on the development of gene-based therapies for patients with unmet medical needs. The Company's lead oncology drug candidate, REQORSA Immunogen therapy drug (quaratusugene ozeplasmid), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA consists of the TUSC2 gene-expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (its ONCOPREX Nanoparticle Delivery System). The Company is also using a different gene therapy delivery system in developing its pre-clinical diabetes candidates, GPX-002 and GPX-003. Its diabetes gene therapy is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Webull offers Genprex Inc stock information, including NASDAQ: GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.